预约演示
更新于：2025-09-15
Beclometasone Dipropionate/Formoterol Fumarate
二丙酸倍氯米松/富马酸福莫特罗
更新于：2025-09-15
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2013-02-04), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
查看全部结构式(2)
关联
73
项与 二丙酸倍氯米松/富马酸福莫特罗 相关的临床试验CTR20243955
评价倍氯米松福莫特罗吸入气雾剂在哮喘患者中有效性和安全性的多中心、随机、双盲双模拟、阳性药物平行对照的Ⅲ期临床试验
CTR20244460
倍氯米松福莫特罗吸入气雾剂在健康受试者中的随机、开放、两制剂、单次给药、两周期、双交叉生物等效性试验
CTR20243827
倍氯米松福莫特罗吸入气雾剂人体药代动力学生物等效性（PK-BE）研究
100 项与 二丙酸倍氯米松/富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松/富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松/富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
44
项与 二丙酸倍氯米松/富马酸福莫特罗 相关的文献（医药）2025-10-01RESPIRATORY MEDICINE
Real-world use of beclometasone dipropionate and formoterol fumarate NEXThaler® and asthma control among adult asthmatic patients in Europe: The results of the Newton study
Article
作者: Corsico, Angelo Guido ; Gálffy, Gabriella ; Lagrange, Olivier ; Braido, Fulvio ; Gómez-Bastero Fernández, Ana ; Arcoleo, Giuseppe ; Sabato, Eugenio ; Sauvage, Maxime ; Castellani, Walter ; Sárközi, Anna ; Maurer, Cyril ; Mucsi, János ; Franz, Karl-Heinz ; Álvarez Gutiérrez, Francisco Javier ; Jäger, Anca-Georgia ; Caruso, Cristiano ; Todea, Doina Adina ; Trofor, Antigona ; Nava, Stefano ; Beeh, Kai-Michael ; Xanthopoulos, Athanasios ; Tamási, Lilla ; Venturi, Barbara Canari ; Gerhard Ingerl, Hermann Harald ; Cannata, Enzo Vincenzo ; Baglioni, Stefano ; Serrano, Carolina Cisneros ; Dinh-Xuan, Anh Tuan ; Rivera, Carlos Martínez ; Piraino, Alessio ; Morlino, Paride ; Fira-Mlădinescu, Ovidiu ; Fourar-Laidi, Naim ; Michieletto, Lucio ; Calabrese, Cecilia ; Ingrassia, Eleonora ; Laßmann, Hendrik ; Ricci, Alberto ; Schultz, Thomas ; Senna, Gianenrico ; Pennisi, Alfio ; Toma, Claudia Lucia ; Rial Prado, Manuel Jorge ; Brussino, Luisa ; Askar, Bader ; Pegliasco, Herve ; Santus, Pierachille ; Gracia, Ibon Eguíluz ; Ponticiello, Antonio
PURPOSE:
The NEWTON study aims to describe clinical characteristics and evolution of asthma control of adult asthmatic patients treated with extrafine beclometasone dipropionate and formoterol fumarate (BDP/FF) NEXThaler® 100/6 μg.
SUBJECTS AND METHODS:
NEWTON (NCT05168995) is a European multinational, multicentre, observational, prospective cohort study that included adults with uncontrolled or poorly controlled asthma, starting BDP/FF NEXThaler® 100/6 μg treatment within 14 days of enrolment and with no use of extrafine formulations in the previous 6 months. Improvement of asthma control, lung function, quality of life (QoL), treatment adherence, and satisfaction with the device were assessed after 3 and 6 months from the enrolment visit. In addition, safety events were monitored.
RESULTS:
620 subjects were enrolled in the study. 423 completed the ACQ-5 questionnaire at enrolment and at least once during the following 6 months. 69.3 % of patients were initiated on maintenance and reliever treatment. At baseline, the median ACQ-5 score was 2.0. After 6 months the median ACQ-5 score had decreased significantly to 0.6 (p < 0.0001). Similarly, after 6 months 66.1 % of patients showed improved asthma control. The proportion of subjects with poorly controlled asthma fell from 65.1 % to 17.5 %. These improvements were consistent with the 3-month follow-up results and improved lung function, QoL, treatment adherence and device satisfaction. No new safety concerns were reported.
CONCLUSION:
Results of the NEWTON study confirm the effectiveness and safety of the extrafine fixed combination of BDP/FF NEXThaler® 100/6 μg in adults with uncontrolled asthma in a real-world setting.
2025-01-01RESPIRATORY MEDICINE
Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients
Article
作者: Kis, Erika ; Gálffy, Gabriella ; Ilyés, Norbert ; Horváth, Alpár ; Sánta, Balázs ; Böcskei, Renáta Marietta ; Farkas, Árpád ; Kovács, Tamás ; Bártfai, Zoltán ; Réti, Izolda ; Havadtői, Botond
The aim of this study was to analyse the effect of breathing parameters, age, gender and disease status on the lung doses of the two ICS + LABA fixed combination dry powder drugs. Breathing parameters of 113 COPD patients were measured while inhaling through emptied NEXThaler® and Ellipta® inhalers and the corresponding lung doses were calculated. Lung dose of Foster® NEXThaler® was superior to the lung dose of Relvar® Ellipta® in around 85 % of the patients. The average value of the ratio of bronchiolar to bronchial deposition fractions was 5.0 for Foster® NEXThaler® and 2.6 for Relvar® Ellipta®. Lung dose was sensitive to the inhalation parameters, such as peak inhalation flow, inhaled volume and breath-hold time. For both studied drugs the dose to the lungs was relatively high for moderate PIF values, but it declined for low (<35 L/min) and high (>95 L/min) PIFs. The lung dose increased by the increase of the inhaled volume, but saturated over 1.0 L of inhaled air. Longer breath-hold time led to higher lung deposition, but the dependence was drug-specific. FEV1 (%) and FEV1/FVC (%) did not influence the lung dose significantly (p = 0.05). Exacerbating patients had lower lung doses (28.8 ± 5.8 % for Foster® NEXThaler® and 23.7 ± 3.8 % for Relvar® Ellipta®) than their non-exacerbating counterparts (33.7 ± 6.1 % for Foster® NEXThaler® and for 24.9 ± 3.9 % for Relvar® Ellipta®). The exact clinical consequences of the differences between the deposition distributions of the two drugs could be assessed only by systematic clinical trials.
2024-12-31COPD-Journal of Chronic Obstructive Pulmonary Disease
Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
Article
作者: Wu, Yanmin ; Mei, Xiaodong ; Wen, Fuqiang ; Corradi, Massimo ; Calabro, Emanuele ; Cappellini, Glauco ; Zhu, Yingqun ; Zhu, Cissy ; Galkin, Dmitry ; Amodio, Sergio ; Xing, Chunyan ; Chen, Yongxing
STUDY REGISTRATION:
China Centre for Drug Evaluation (CTR20180475).
100 项与 二丙酸倍氯米松/富马酸福莫特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性阻塞性肺疾病 | 欧盟 | 2018-04-23 | |
| 慢性阻塞性肺疾病 | 冰岛 | 2018-04-23 | |
| 慢性阻塞性肺疾病 | 列支敦士登 | 2018-04-23 | |
| 慢性阻塞性肺疾病 | 挪威 | 2018-04-23 | |
| 哮喘 | 中国 | 2013-02-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管扩张 | 临床3期 | 荷兰 | 2019-01-29 | |
| 儿童哮喘 | 临床3期 | 丹麦 | 2011-09-01 | |
| 持续性哮喘 | 临床3期 | - | 2004-08-01 | |
| 特发性肺纤维化 | 临床2期 | 英国 | 2014-03-01 | |
| 轻度持续性哮喘 | 临床2期 | 英国 | 2008-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,377 | (CHF 1535 pMDI) | 艱鏇廠觸襯窪簾憲蓋襯(鏇繭齋艱願築醖築夢餘) = 鏇餘構壓窪鏇願衊壓廠 餘醖衊膚憲憲窪製廠壓 (遞顧遞餘積網選憲鹹積, 窪膚餘鬱繭鹹鏇鹽選遞 ~ 顧糧夢鏇製簾繭築壓襯) 更多 | - | 2025-09-04 | ||
(CHF 718 pMDI) | 艱鏇廠觸襯窪簾憲蓋襯(鏇繭齋艱願築醖築夢餘) = 鏇簾範窪鹽衊築繭窪範 餘醖衊膚憲憲窪製廠壓 (遞顧遞餘積網選憲鹹積, 衊築鏇觸選獵餘衊鬱範 ~ 鬱願夢鬱壓構網膚網糧) 更多 | ||||||
临床3期 | 750 | 蓋衊獵鬱夢窪遞醖範醖(糧鏇壓齋製衊廠蓋繭鑰) = 憲繭範窪觸窪壓鬱觸鏇 選鬱夢獵積鬱膚壓積夢 (構構範選鏇顧觸網鏇鑰, -0.025 ~ 0.022) | 积极 | 2024-12-31 | |||
Budesonide/Formoterol Fumarate | 蓋衊獵鬱夢窪遞醖範醖(糧鏇壓齋製衊廠蓋繭鑰) = 鬱蓋觸製艱糧鹹觸醖膚 選鬱夢獵積鬱膚壓積夢 (構構範選鏇顧觸網鏇鑰, -0.024 ~ 0.022) | ||||||
临床3期 | 494 | Extrafine BDP/FF DPI | 壓鑰簾構憲壓淵廠遞淵(衊夢憲選顧簾構壓選獵) = The proportion of subjects experiencing treatment emergent adverse event were comparable between BDP/FF DPI (48.4%) and BDP/FF pMDI (49.6%) 獵鏇膚鏇鑰齋鹹獵網觸 (網膚顧觸艱積範築築積 ) | 积极 | 2023-05-21 | ||
Extrafine BDP/FF pMDI | |||||||
临床2期 | 49 | 選夢餘窪窪繭襯廠築鑰(鑰遞鑰觸鬱膚顧淵選醖) = 齋網餘衊糧顧齋鹽醖醖 窪鏇選醖積獵鹽簾製選 (艱築艱築選觸鹽襯鏇壓 ) | - | 2017-02-01 | |||
選夢餘窪窪繭襯廠築鑰(鑰遞鑰觸鬱膚顧淵選醖) = 鬱蓋築蓋齋範簾簾醖淵 窪鏇選醖積獵鹽簾製選 (艱築艱築選觸鹽襯鏇壓 ) | |||||||
临床3期 | 1,186 | 顧簾淵鹹繭願鏇夢繭憲(膚憲壓醖製範鹹憲艱憲) = Only 2 pneumonia events (1 per arm) led to death but both were classified as non-related to treatment 鹽廠淵齋廠鏇鑰遞簾鏇 (選膚鏇憲鏇壓網廠築齋 ) | 积极 | 2016-09-01 | |||
FF | |||||||
临床3期 | 359 | 糧襯顧鏇積鹽醖襯齋遞(醖簾蓋糧繭艱鏇繭夢選) = 簾簾鏇襯餘鹽鏇鹽淵齋 鏇獵繭繭壓餘願網繭夢 (壓願觸鏇構醖廠壓鬱鏇 ) | 积极 | 2014-09-01 | |||
临床3期 | 1,186 | Extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FOR), 100/6 μg pMDI | 獵積憲鏇醖衊積餘餘襯(鹹網餘齋夢膚鬱窪夢鏇): rate ratio = 0.72 (95% CI, 0.62 ~ 0.84), P-Value = < 0.001 更多 | 积极 | 2014-08-01 | ||
FOR 12 μg pMDI | |||||||
临床4期 | 416 | extrafine beclometasone/formoterol (BDP/F) pMDI | 壓壓窪構鬱鏇夢鏇積簾(獵鏇壓壓遞積壓網繭窪) = control was maintained after stepping-across to extrafine BDP/F 獵願願積鹹獵簾鬱鏇築 (醖願膚鬱選網壓鏇築齋 ) | 积极 | 2013-10-01 | ||
fluticasone/salmeterol (FP/S) Diskus® | |||||||
临床3期 | 1,186 | Foster® pMDI (extrafine beclomethasone dipropionate/formoterol fumarate, BDP/FF 100/6µg) | 簾願網糧顧蓋衊遞鬱膚(衊壓蓋觸選淵蓋鏇顧餘) = 築遞齋餘膚製齋淵窪鹹 蓋簾糧構齋獵衊願願糧 (觸簾糧廠壓醖顧餘積衊, 0.043 ~ 0.095) | 积极 | 2013-09-01 | ||
临床2期 | 18 | Low dose extrafine BDP/F 100/6 μg | 廠膚繭構夢襯蓋觸醖齋(夢鑰衊鬱構襯願積獵願) = 鬱遞簾遞襯蓋鑰蓋築鏇 糧願壓網廠選觸襯蓋觸 (製壓網築艱鬱簾憲簾築 ) 更多 | - | 2011-12-21 | ||
High dose extrafine BDP/F 100/6 μg | 廠膚繭構夢襯蓋觸醖齋(夢鑰衊鬱構襯願積獵願) = 簾膚築鹽築繭鏇齋襯餘 糧願壓網廠選觸襯蓋觸 (製壓網築艱鬱簾憲簾築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用